The case for & against
Bull & Bear analysis
Iovance Biotherapeutics (NASDAQ: IOVA) is a pioneering biotechnology company specializing in cell therapies to combat solid tumors, particularly through its proprietary Tumor-Infiltrating Lymphocyte (TIL) therapy. Positioned within the burgeoning field of immuno-oncology, Iovance is emerging as a leader focused on innovative therapies that harness the immune system to treat cancer. The company has made significant inroads into regulatory approvals with its lead product, Antagni, and is expanding its presence internationally while aiming for EBITDA growth through enhanced manufacturing capabilities and an expanding pipeline.
Bull says
- ↑Q1 revenue $71M (+45% YoY); 2026 forecast $350–370M (+36%).
- ↑Gross margin ~41%; cash $319M funds operations into 2028.
- ↑Pursuing FDA expedited pathways to accelerate new therapy approvals.
- ↑Expanding Authorized Treatment Centers increases patient referrals.
- ↑Strong Buy consensus; $9.50 median PT implies ~125% upside.
- ↑High 13F ownership, solid liquidity, and attractive yield support flexibility.
Bear says
- ↓Negative earnings yield and -123.9% profit margin highlight unprofitable operations.
- ↓Manufacturing capacity cuts for facility upgrades risk near-term supply.
- ↓Regulatory delays could push back revenue from new indications.
- ↓Annual cash burn (~$245M) strains finances despite $319M runway.
- ↓Intensifying oncology competition and high stock volatility heighten risks.
- ↓Community infusion expansion may underdeliver, limiting patient referrals.
Investment themes with IOVA
Genetic and drug innovations driving medical breakthroughs
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- We're seeing good enrollment until mid-year one. Obviously, we do a lot of it outside the United States because it's easier outside the United States with standard of care. But it's a study that we think is well-designed. We have very good FDA feedback on the design of the study. We expect good things for TIL bands, and we think that TIL therapy in the frontline setting, especially combined with Pembrolizumab, can vastly improve the chances of a good overall survival outcome for patients.
- First quarter revenue of $71 million grew roughly 45% year-over-year, driven by strong antagony demand.
- Antagony revenue of $60 million increased by 38% year-over-year on strong demand growth, our second highest quarterly revenue for MTagV.
Bear points
- So we're now all the way well into 2026, as you can see in the press release today.
- I can't really say much more about conference stuff, except that we've guided, obviously, to 2026 disclosure at a medical meeting, and we continue to plan to do that.